Pharmaceutical cost savings from the treatment of oncology patients in clinical trials.

Autor: Gómez Mediavilla B; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain., Lanza León P; Departamento de Economía, Universidad de Cantabria, Santander, Spain; Health Economics Research Group, Valdecilla Biomedical Institute Research - IDIVAL, Santander, Spain. Electronic address: paloma.lanza@unican.es., Martínez Callejo V; Department of Hospitalary Phramacy, Hospital universitario Marqués de Valdecilla, Santander, Spain., Cantarero Prieto D; Departamento de Economía, Universidad de Cantabria, Santander, Spain; Health Economics Research Group, Valdecilla Biomedical Institute Research - IDIVAL, Santander, Spain., Lanza Postigo M; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain., Salcedo Lambea M; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain., Blanco Mesonero Y; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain., Ochagavia Sufrategui M; Department of Hospitalary Phramacy, Hospital universitario Marqués de Valdecilla, Santander, Spain., Durán I; Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Sarabia Cobo CM; Department of Nursing, Universisty of Cantabria, Santander, Spain; Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain.

Publikováno v: Biomedical journal [Biomed J] 2024 Apr 26, pp. 100742. Date of Electronic Publication: 2024 Apr 26.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.